Ranitidine Hydrochloride | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Ranitidine Hydrochloride
Health Canada Patents

AMI Lifesciences is Driven by Chemistry. Powered by People.

Contact Supplier

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Contact Supplier

Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.

Contact Supplier

Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

Contact Supplier

Quotient Sciences- Molecule to Cure. Fast.

Contact Supplier

pharmacompass-2-m-2025-08-25

Ranitidine Hydrochloride

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

83 API Suppliers, 30 USDMF, 14 CEP/COS, 2 JDMF, 4 EU WC, 47 KDMF, 9 NDC API, 6 Listed Suppliers, $ API Reference Price

83 API Suppliers
30 USDMF
14 CEP/COS
2 JDMF
4 EU WC
47 KDMF
9 NDC API
6 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

170 FDF Dossiers, 121 FDA Orange Book, 21 Europe, 9 Canada, 19 Listed Dossiers

170 FDF Dossiers
121 FDA Orange Book
21 Europe
9 Canada
19 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 300MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 25MG BASE/ML, TABLET;ORAL - EQ 75MG BASE, TABLET;ORAL - EQ 150MG BASE

TABLET;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 300MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
INJECTABLE;INJECTION - EQ 25MG BASE/ML
TABLET;ORAL - EQ 75MG BASE
TABLET;ORAL - EQ 150MG BASE

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 4 Rochem International Inc, 8 SPI Pharma, 11 DKSH, 1 Pharm-RX Chemical, 3 Boai NKY Pharmaceuticals Ltd, 8 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 5 Kirsch Pharma, 4 ACG Worldwide, 13 Actylis, 1 Aeon Procare, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 16 BASF, 1 Bioplus Life Sciences, 1 Clariant, 10 Corel Pharma Chem, 6 DFE Pharma, 1 Esteem Industries, 3 Finar, 9 Gangwal Chemicals, 4 Ideal Cures, 4 Ingredion Pharma Solutions, 19 Kerry, 3 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 10 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 1 Novo Excipients, 2 Pharmatrans-Sanaq, 7 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 32 Roquette, 13 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 Silverline Chemicals, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Vertellus, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

59 Fillers, Diluents & Binders, 45 Coating Systems & Additives, 27 Thickeners and Stabilizers, 26 Disintegrants & Superdisintegrants, 24 Parenteral, 22 Film Formers & Plasticizers, 22 Granulation, 22 Taste Masking, 22 Direct Compression, 21 Controlled & Modified Release, 20 Solubilizers, 19 Topical, 16 Lubricants & Glidants, 14 Co-Processed Excipients, 9 Chewable & Orodispersible Aids, 9 Empty Capsules, 8 Emulsifying Agents, 7 Rheology Modifiers, 7 API Stability Enhancers, 6 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

59 Fillers, Diluents & Binders
45 Coating Systems & Additives
27 Thickeners and Stabilizers
26 Disintegrants & Superdisintegrants
24 Parenteral
22 Film Formers & Plasticizers
22 Granulation
22 Taste Masking
22 Direct Compression
21 Controlled & Modified Release
20 Solubilizers
19 Topical
16 Lubricants & Glidants
14 Co-Processed Excipients
9 Chewable & Orodispersible Aids
9 Empty Capsules
8 Emulsifying Agents
7 Rheology Modifiers
7 API Stability Enhancers
6 Surfactant & Foaming Agents
5 Coloring Agents
4 Vegetarian Capsules
1 Soft Gelatin

DIGITAL CONTENT

120 News #PharmaBuzz

120 News #PharmaBuzz

GLOBAL SALES INFORMATION

7 Regulatory FDF Prices, 3 Annual Reports

7 Regulatory FDF Prices
3 Annual Reports

MARKET PLACE

20 APIs

20 APIs

PATENTS & EXCLUSIVITIES

4 Health Canada Patents

4 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 2 JP, 1 Others

3 EDQM
2 JP
1 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 22 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

4 All

01 4GlaxoSmithKline Inc.

filter Patent Reset all filters

4 All

01 41329130

filter Product Reset all filters

4 All

01 4Ranitidine hydrochloride

filter Dosage Reset all filters

4 All

01 2Granules

02 2Tablet

filter Exp Date Reset all filters

4 All

01 42011-05-03

Product Main Page

01

GlaxoSmithKline Inc.

Ranitidine hydrochloride

Coatings Trends

Not Confirmed

GlaxoSmithKline Inc.

Coatings Trends

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2011-05-03

Date Granted : 1994-05-03

Ranitidine hydrochloride

Brand Name : ZANTAC EFFERVESCENT

Patent Number : 1329130

Filing Date :

Strength per Unit : 300 mg

Dosage Form : Granules

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2011-05-03

Date Granted : 1994-05-03

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

GlaxoSmithKline Inc.

Ranitidine hydrochloride

Coatings Trends

Not Confirmed

GlaxoSmithKline Inc.

Coatings Trends

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2011-05-03

Date Granted : 1994-05-03

Ranitidine hydrochloride

Brand Name : ZANTAC

Patent Number : 1329130

Filing Date :

Strength per Unit : 150 mg

Dosage Form : Granules

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2011-05-03

Date Granted : 1994-05-03

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

GlaxoSmithKline Inc.

Ranitidine hydrochloride

Coatings Trends

Not Confirmed

GlaxoSmithKline Inc.

Coatings Trends

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2011-05-03

Date Granted : 1994-05-03

Ranitidine hydrochloride

Brand Name : ZANTAC

Patent Number : 1329130

Filing Date :

Strength per Unit : 150 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2011-05-03

Date Granted : 1994-05-03

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

GlaxoSmithKline Inc.

Ranitidine hydrochloride

Coatings Trends

Not Confirmed

GlaxoSmithKline Inc.

Coatings Trends

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2011-05-03

Date Granted : 1994-05-03

Ranitidine hydrochloride

Brand Name : ZANTAC

Patent Number : 1329130

Filing Date :

Strength per Unit : 300 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2011-05-03

Date Granted : 1994-05-03

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!